Related Experiment Video
Updated: Apr 12, 2026
13:19
Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery
Published on: April 26, 2024
4.2K
Clinical development of siltuximab
Christine C Davis1, Katherine S Shah, Mary Jo Lechowicz
1Department of Pharmaceutical Services, Emory Healthcare, Atlanta, GA, USA, christine.davis@emoryhealthcare.org.
Current Oncology Reports
|May 20, 2015
Summary
Siltuximab is the first FDA-approved treatment for idiopathic multicentric Castleman's disease (MCD), targeting interleukin-6 (IL-6). It offers symptomatic relief and improves quality of life for patients with this rare condition.
Area of Science:
- Immunology
- Oncology
- Pharmacology
Background:
- Idiopathic multicentric Castleman's disease (MCD) is a rare, non-clonal lymphoproliferative disorder characterized by hypercytokinemia, primarily interleukin-6 (IL-6).
- Common symptoms of MCD include fever, night sweats, weight loss, and fatigue, significantly impacting patient quality of life.
Purpose of the Study:
- To review the clinical development and pharmaceutical approval of siltuximab.
- To highlight siltuximab's role as the first FDA-approved treatment for idiopathic multicentric Castleman's disease.
Main Methods:
- Review of clinical trial data and regulatory submissions for siltuximab.
- Analysis of siltuximab's efficacy and safety profile in MCD and other investigated diseases.
Main Results:
- Siltuximab, a chimeric monoclonal antibody targeting IL-6, received FDA approval in 2014 for MCD.
- Efficacy in MCD is primarily demonstrated through systemic symptomatic response and quality of life improvements, with limited complete radiographic responses.
- Siltuximab showed no significant benefit in multiple myeloma, non-Hodgkin lymphomas, and solid tumors.
Conclusions:
- Siltuximab represents a significant therapeutic advancement for idiopathic multicentric Castleman's disease.
- Its importance lies in managing symptoms and enhancing quality of life for patients with this rare disorder.
